Biotech organizations face a series of high-stakes decisions when designing their clinical development programs. These decisions involve balancing speed, cost, regulatory risk, and trial delivery. Too often, companies default to traditional study designs and endpoints—missing opportunities to reduce patient numbers, streamline approval pathways, and enhance overall efficiency. This hesitation may be driven by a lack of awareness of available options, concerns about regulatory acceptance, or implementation challenges. However, by leveraging close collaboration between biopharma scientific leaders, statistical design experts, and regulatory strategists, companies can identify optimal trial designs that enhance success rates, reduce risk and cost, increase label coverage, and accelerate timelines. In some cases, these efficiencies can translate into savings of years of development time and tens of millions of dollars.
In this panel-led session, brought to you by MMS, industry experts will explore how strategic trial design innovations can improve R&D outcomes. Aiden Flynn, SVP of Statistical Consulting; Amanda Beaster, Director of Regulatory Strategy; and Irving Dark, Board Member and Industry Biometrics Thought Leader, will discuss real-world case examples showcasing design optimization strategies alongside regulatory best practices. They’ll examine the power of statistical simulation tools like KerusCloud and explore approaches such as:
- Innovative trial designs that reduce risk and accelerate development
- Model-informed drug development for data-driven decision-making
- Statistical simulation techniques to maximize the probability of success
- Regulatory risk management when pursuing non-standard designs
At the conclusion of the discussion, attendees will have the opportunity to engage directly with the experts in an interactive Q&A session. Join us for this insightful session and discover how advanced trial design strategies can unlock new pathways to success!
- Discover how data and technology are reshaping trial design strategies.
- Gain insights into regulatory trends and best practices for innovative, adaptive, and traditional trial designs
- Understand how industry peers are integrating innovative approaches to increase efficiency and reduce risk
- How innovative trial designs, optimized endpoints, statistical simulations, and virtual patient populations can accelerate approvals and reduce patient burden.
- How tools like KerusCloud can streamline development by modeling trial scenarios, optimizing patient numbers, and improving decision-making.
- How aligning scientific, statistical, and regulatory teams from the outset drives more efficient trial strategies.
- What regulatory best practices should be adopted alongside innovative design approaches.
- Clinical development and operations professionals
- Regulatory and data strategy teams
- Biotech and pharmaceutical executives
- Medical affairs and R&D leaders
- Anyone interested in the future of clinical trial design
Who is this webinar for?
This webinar and panel discussion is designed for biotech and pharmaceutical leaders, clinical development professionals, biostatisticians, and regulatory decision-makers seeking actionable strategies to optimize clinical trial design. Whether you are involved in trial planning, statistical modeling, or regulatory strategy, this session will provide insights into leveraging Real-World Data, adaptive trial designs, and statistical simulation to enhance efficiency, reduce risk, and accelerate approvals.
Will there be a recording available?
Yes, a recording will be provided to all registered attendees following the scheduled event.
Where can I get more information on the content presented?
To connect with the presenters, email info@mmsholdings.com and our team will connect you with the right person.